|Bid||9.17 x 2200|
|Ask||9.21 x 4000|
|Day's Range||8.90 - 9.33|
|52 Week Range||3.58 - 12.44|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.67|
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m. E.T.
Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, combined with two adjuvants, alum and Dynavax Technologies Corporation’s (NASDAQ: DVAX) CpG 1018. Over 4,000 volunteers in the U.K. have been randomized in the Phase 3 trial “Cov-Compare,” which compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001,
What happened Shares of Dynavax Technologies (NASDAQ: DVAX) were up by 3.6% as of 11:38 a.m. EDT on Thursday after having gained as much as 6.9% earlier in the session. The stock's rise came following the company's announcement that it has signed a deal with Bavarian Nordic to market and distribute its hepatitis B vaccine Heplisav B in Germany.